PreprintCited by 197SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinationsvaccines and immunoinformatics approaches

Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2

Open access
Israelow, Benjamin, Mao, Tianyang, Klein, Jonathan, Song, Eric, Menasche, Bridget, Omer, Saad B., Iwasaki, Akiko·2021·Science Immunology

Preprint — published as 10.1126/sciimmunol.abl4509 · Paper page

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 160 million infections and more than 3 million deaths worldwide. While effective vaccines are currently being deployed, the adaptive immune determinants which promote viral clearance and confer protection remain poorly defined. Using mouse models of SARS-CoV-2, we demonstrate that both humoral and cellular adaptive immunity contributes to viral clearance in the setting of primary infection. Furthermore, we find that either convalescent mice, or mice that receive mRNA vaccination are protected from both homologous infection and infection with a variant of concern, B.1.351. Additionally, we find this protection to be largely mediated by antibody response and not cellular immunity. These results highlight the in vivo protective capacity of antibodies generated to both vaccine and natural infection. One-Sentence Summary: Defining the roles of humoral and cellular adaptive immunity in viral clearance and protection from SARS-CoV-2 and a variant of concern.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2021.05.19.444825

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Neutralizing antibodies are a likely correlate of protection against SARS-CoV-2 infection.

    “Neutralizing antibodies are a likely correlate of protection against SARS-CoV-2 infection, as suggested by vaccine efficacy studies, preclinical studies in mice and non-human primates, and data from the early use of convalescent plasma in elderly patients 4,5,10,13,14,18,23 .”
  • T cells might limit disease progression when neutralizing antibody titres are low.

    “Although it is increasingly recognized that neutralizing antibodies dominate protection against initial infection 4,13 , T cells might limit disease progression 5 when neutralizing antibody titres are low 14 .”
  • There is increasing evidence that neutralizing responses are a correlate of protection.

    “There is increasing evidence that neutralizing responses are a correlate of protection [4][5][6] .”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 52 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
  2. was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The copyright holder for this preprint (which this version posted May 19, 2021. ; https://doi.org/10.1101/2021.05.19.444825 doi: bioRxiv preprint

Cited by

Sorted by citations

Authors
Israelow, B., Mao, T., Klein, J., Song, E., Menasche, B., Omer, S. B., & Iwasaki, A.
Affiliations
  • Yale University (US)
  • Howard Hughes Medical Institute (US)
Corresponding author
Iwasaki, Akiko
Venue
Science Immunology
Publisher
openRxiv
Published
2021-05-19
Volume
6
Issue
64
Pages
eabl4509-eabl4509
ISSN
2470-9468 (ISSN-L)
OpenAlex
W3197127917
Cited by
189
References
52
Citations by year
2026: 9 · 2025: 23 · 2024: 26 · 2023: 43 · 2022: 67 · 2021: 21
FWCI
13.06
Type
journal article
Language
en
Open access
Locations
  • Science Immunology (publishedVersion)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion)
Funders
  • Howard Hughes Medical Institute
  • Yale University
  • National Institutes of Health (UL1TR001863)
  • National Cancer Institute (F30CA239444)
  • National Institute of General Medical Sciences (T32GM007205)
  • National Institute of Allergy and Infectious Diseases (R01AI157488, K08AI163493, T32AI007019, T32AI007517)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Keywords
SARS-CoV-2, adaptive immunity, viral clearance, humoral immunity, cell-mediated immunity, antibody response, mRNA vaccination, B.1.351 variant, Omicron variant, COVID-19 protection, mouse model

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review